 With their product RescueFlow®, BioPhausia has a real trump on their hand. BioPhausia AB is quoted on the Stockholm Stock Exchange. |
 Biophausia AB Founded: 1994 Publicly listed: Yes Number of employees: 10 Key business area(s): Research & development, pharmaceuticals Telephone: +46 18 34 99 00 Website Contact |
|
|
| Introduction
of a Life Saver One of the many interesting, aggressive and innovative companies in the Biotech Valley is BioPhausia in Uppsala. Their main product, RescueFlow® is introduced in Europe and approved in nine countries already. ”RescueFlow® was originally developed as an answer to military demand for a low volume effective solution for shock treatment. It is a product, within our core competence areas. After administration of RescueFlow® the circulating blood volume increases rapidly with up to one litre and stays elevated for several hours, even though it is given in a small volume (250 millilitres),” says Lars-Olof Lindbom, Director of Research and Development at BioPhausia. RescueFlow® is a global product Though it was developed on request from the military sector, it has been shown to be useful in prehospital settings as well as Emergency Care and is further developed for use during surgical procedures. RescueFlow® is a global product, registered in nine countries and the work is now focused on finalising the European Distributor Network in order to secure a successful introduction of Specialty products into Europe. Besides the rapid and sustained effect, RescueFlow® improves the microvascular perfusion and microcirculation, which is as important as the volume effect in critically ill patients. ”We are focusing directly on the specialists working with trauma patients on a daily basis. We have received a lot of positive responses from users in the market and it is interesting to see the development” says Claes Thulin, CEO at BioPhausia. “ ‘The effect is unbelievable’ is what many users say when they use it for the first time. “RescueFlow® keeps the patient stabilized after the initial resuscitation and we follow up with the Standard of Care (SOC)” as Dr Mayer a Trauma surgeon at one of the major Trauma Centers in Germany, says. Innovative pharmaceuticals BioPhausia is a pharmaceutical company committed to research within microcirculation, biopolymers and cellular biology. By merging two or more of these fields they are able to develop new and interesting innovative pharmaceuticals. RescueFlow®, for instance, has its place in the fields of biopolymers and microcirculation. Their business idea is to in-license and develop projects in phase two or three, and to effectively market Specialty products on the European Market. Marketing and merchandising of specialised products targeting hospital specialists, is handled by the fully-owned company Medisan Pharmaceuticals AB. ”Our ambition is to become an interesting partner both for hospital specialists and pharmaceutical companies, entering the European market-place. It implies a constant search for new projects and speciality products. Our strategy is to contribute with our level of competence in the various phases of development as well as with the European Distribution Network. We are now established to the extent that we are contacted regarding projects” says Claes Thulin. Besides RescueFlow® we have three develop-ment projects in the areas of Oncology, Transplantation/ Inflammatory oedema and Osteo-arthrosis. BioPhausia’s scientific network BioPhausia’s scientific network is extensive and involves among others the Universities of Bergen, Lund, UCLA and UTMB, Texas together with the Bio-medical Centre at the University of Uppsala, Ludwig Maximilian University of Munich and the University Hospitals of Uppsala and University of Sahlgrenska in Gothenburg and the Karolinska Institute in Stockholm as well as the US Army. The largest owners are Skandia, a Swedish Insurance company and Traction. BioPhausia is quoted on the Stockholm Stock Exchange. |
All Rights Reserved